Dyne Therapeutics, Inc. (DYN) stock
DYNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$17.01−0.98 (-5.45%)
Close on Nov 12, 2026Market cap $3.18BP/E –Yield –
Dyne Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Dyne Therapeutics's total assets was $1.23B at Sep 30, 2026. For fiscal 2025 it was $1.19B, up 71.7% from the year before. The highest annual figure on record is $1.19B in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.19B | +71.7% |
| FY2024 | Dec 31, 2024 | $691.23M | +318.7% |
| FY2023 | Dec 31, 2023 | $165.08M | -46.1% |
| FY2022 | Dec 31, 2022 | $306.33M | -28.0% |
| FY2021 | Dec 31, 2021 | $425.66M | +20.5% |
| FY2020 | Dec 31, 2020 | $353.33M | +2049.8% |
| FY2019 | Dec 31, 2019 | $16.44M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.23B | +42.4% |
| Q2 FY2026 | Jun 30, 2026 | $994.01M | +36.4% |
| Q1 FY2026 | Mar 31, 2026 | $1.08B | +49.8% |
| Q4 FY2025 | Dec 31, 2025 | $1.19B | +71.7% |
| Q3 FY2025 | Sep 30, 2025 | $867.06M | +12.8% |
| Q2 FY2025 | Jun 30, 2025 | $728.99M | -11.7% |
| Q1 FY2025 | Mar 31, 2025 | $721.07M | +38.1% |
| Q4 FY2024 | Dec 31, 2024 | $691.23M | +318.7% |
| Q3 FY2024 | Sep 30, 2024 | $768.84M | +274.6% |
| Q2 FY2024 | Jun 30, 2024 | $825.88M | +228.5% |
| Q1 FY2024 | Mar 31, 2024 | $522.28M | +80.9% |
| Q4 FY2023 | Dec 31, 2023 | $165.08M | -46.1% |
| Q3 FY2023 | Sep 30, 2023 | $205.24M | -31.5% |
| Q2 FY2023 | Jun 30, 2023 | $251.42M | -26.1% |
| Q1 FY2023 | Mar 31, 2023 | $288.64M | -25.6% |
| Q4 FY2022 | Dec 31, 2022 | $306.33M | -28.0% |
| Q3 FY2022 | Sep 30, 2022 | $299.68M | -35.8% |
| Q2 FY2022 | Jun 30, 2022 | $340.03M | -27.2% |
| Q1 FY2022 | Mar 31, 2022 | $387.76M | -21.1% |
| Q4 FY2021 | Dec 31, 2021 | $425.66M | +20.5% |
| Q3 FY2021 | Sep 30, 2021 | $466.88M | +22.4% |
| Q2 FY2021 | Jun 30, 2021 | $467.15M | +2742.2% |
| Q1 FY2021 | Mar 31, 2021 | $491.71M | – |
| Q4 FY2020 | Dec 31, 2020 | $353.33M | – |
| Q3 FY2020 | Sep 30, 2020 | $381.47M | – |
| Q4 FY2019 | Dec 31, 2019 | $16.44M | – |
See a number that looks wrong?